Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

Microbial Drug Factories
Synthetically engineered micro-örganisms could provide a cheap way to manufacture drugs

SOURCE: “Production of the Antimalarial Drug Precursor Artemisinic Acid in Engineered Yeast” D. K. Ro et al.Nature 440(7086): 940-943

RESULTS: Dae-Kyun Ro, Jay Keasling (who wrote a “Notebook” entry), and colleagues at the University of California, Berkeley, have genetically engineered yeast to produce large quantities of artemisinic acid, a precursor to the malaria drug artemisinin.

WHY IT MATTERS: Artemisinin combination therapies are an effective treatment for malaria. But the drugs, which are derived from the sweet wormwood tree, are expensive and in short supply. More-efficient manufacturing methods could reduce the cost of the malaria drugs to the point that a larger number of people in poor countries could afford them. The work also illustrates the great potential of synthetic biology – the attempt to design and create organisms to perform specific functions.

METHODS: The researchers re-designed the metabolic pathways of yeast to more efficiently make an artemisinin precursor called amorphadiene, which plants naturally make in small quantities. Using a newly identified wormwood gene, they further engineered the yeast to complete the last few steps of the synthesis process to create artemisinic acid.

NEXT STEPS: Keasling’s team will continue to fine-tune the system to make it even more efficient and therefore more cost effective. It will also scale up the manufacturing process in collaboration with Amyris Biotechnologies, a company in Emeryville, CA, that was founded to commercialize the technology.

From the Labs: Nanotechnology
From the Labs: Information Technology

0 comments about this story. Start the discussion »

Tagged: Biomedicine

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me